MK 383

Known as: MK-383 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2005
01219932005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
OBJECTIVE We tested the hypothesis that simultaneous inhibition of the endothelial integrin alpha(v)beta(3) and the platelet… (More)
Is this relevant?
2002
2002
The platelet integrin alphaIIb beta3 (GPIIb/IIIa) acts as a receptor for fibrinogen, playing a critical role in platelet… (More)
Is this relevant?
2000
2000
Several preclinical studies have found a poor correlation between the ex vivo platelet inhibitory potency and the in vivo… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
1999
1999
In vivo antithrombotic efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) was studied with respect to their… (More)
Is this relevant?
1998
1998
Platelet dysfunction probably contributes to bleeding associated with ventricular assist devices (VADs). Previous evidence… (More)
Is this relevant?
1997
1997
We determined the effects of combining the glycoprotein IIb/IIIa inhibitor tirofiban (MK-383, Aggrastat) and ticlopidine on… (More)
Is this relevant?
1996
1996
OBJECTIVES The objectives of this double-blind, placebo-controlled, randomized dose-ranging study were 1) to examine the safety… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
1994
1994
MK-383 (L-tyrosine, N-(n-butylsulfonyl)-O-[4-butyl(4-piperidinyl)], monohydrochloride monohydrate) is a potent and specific… (More)
Is this relevant?
1994
1994
MK-383 is a novel, non-peptide fibrinogen receptor antagonist. A sensitive and specific radioimmunoassay has been developed for… (More)
Is this relevant?
1993
1993
BACKGROUND Fibrinogen-dependent cross-linking of glycoprotein (GP) IIb/IIIa on activated platelets is the final mechanism leading… (More)
Is this relevant?